Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07707258

Remimazolam Combined With Oliceridine for Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy

This study aims to evaluate the sedative efficacy and safety of remimazolam combined with oliceridine in elderly patients undergoing painless gastrointestinal endoscopy. Elderly patients often face higher risks of respiratory and hemodynamic depression during clinical sedation. This trial will investigate whether the combination of remimazolam and oliceridine can provide stable sedation, maintain stable vital signs, and reduce the incidence of adverse events such as hypoxemia and postoperative cognitive fluctuation in this vulnerable population.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Baoshan District Dachang Hospital (Renji Hospital Baoshan Branch)

Shanghai, Shanghai Municipality, 200444, China

Location status: Recruiting

Location contact

Linglong Gong, MD

CONTACT

[email protected]

+86-17317107780

About this study

This is a clinical study conducted at the Baoshan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine. The study will strictly adhere to ethical guidelines, and all research activities will be carried out after receiving full approval from the Ethics Committee.

Elderly participants will be enrolled based on predefined inclusion criteria with comprehensive vulnerability assessments. During the gastrointestinal endoscopy procedure, vital signs, particularly oxygen saturation (SpO2) and its duration of depression, will be monitored closely. To address potential educational bias in cognitive assessments, the study will utilize the Mini-Mental State Examination (MMSE) stratified by years of education alongside the Montreal Cognitive Assessment (MoCA) to comprehensively evaluate postoperative cognitive outcomes. Follow-up assessments will be systematically conducted at designated time points (e.g., 1 week, 1 month, 3 months, and 6 months) post-procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elderly individuals scheduled to undergo painless gastrointestinal endoscopy.
  • Age between 65 and 80 years.
  • Body mass index (BMI) between 18 and 30 kg/m².
  • American Society of Anesthesiologists (ASA) physical status I-III (ASA III patients eligible only with mild-to-moderate dysfunction of a single organ system, without severe organ failure, and considered able to tolerate the procedure).
  • Fried frailty phenotype score < 3.
  • Mini-Mental State Examination (MMSE) score ≥ 27.
  • Provision of written informed consent by the patient or legal representative.

Exclusion criteria

  • Allergy or contraindication to remimazolam, oliceridine, or sufentanil.
  • Liver or renal failure (Child-Pugh class C or eGFR < 30 mL/min).
  • Systemic infection, immunosuppression, coagulation disorder, upper gastrointestinal bleeding, or intestinal obstruction.
  • History of opioid dependence or long-term use of psychotropic drugs.
  • Difficult airway or severe respiratory dysfunction.
  • Cognitive impairment, psychiatric disease, or inability to cooperate with assessment.
  • New York Heart Association (NYHA) functional class III or higher[cite: 3].
  • Fried frailty phenotype score ≥ 3.
  • Use of sedative or analgesic drugs within 24 hours before enrollment.

Treatment and study plan

Remimazolam Tosilate for injection

Drug

Administered intravenously for sedation induction and maintenance during gastrointestinal endoscopy. The dosage will be titrated according to the patient's sedation depth and clinical response.

Other names: Remimazolam Tosilate, Remimazolam

Oliceridine Fumarate

Drug

Administered intravenously before or during the procedure to provide stable analgesic cooperation and optimize procedural sedation quality in elderly patients.

Other names: Oliceridine

Primary outcomes

  1. Incidence of hypoxemia

    Time frame: From initiation of sedation induction to completion of the gastrointestinal endoscopic procedure, approximately 30 minutes.

    The proportion of participants who experience at least one episode of hypoxemia during procedural sedation for gastrointestinal endoscopy. Hypoxemia is defined as peripheral oxygen saturation (SpO₂) < 90%. SpO₂ will be continuously monitored throughout the observation period.

Secondary outcomes

  1. Incidence of Hypotension

    Time frame: From the pre-induction baseline assessment to transfer to the post-anesthesia care unit, up to 1 hour.

    The proportion of participants who experience at least one episode of hypotension during procedural sedation. Hypotension is defined as a decrease in mean arterial pressure (MAP) of more than 20% from the pre-induction baseline. MAP will be recorded at baseline and monitored throughout the observation period.

  2. Sedation success rate

    Time frame: From the start of sedation induction to the completion of the endoscopic procedure

    The proportion of patients who achieve a satisfactory sedation depth (MOAA/S score ≤ 1) without the need for rescue sedative medications.

Study contacts

Contact information is provided by the study sponsor or research team.

Ling long Gong, PhD

CONTACT

[email protected]

+86-17317107780

Sponsors and collaborators

Lead sponsor

Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Other

Registry information

Official study title

Hemodynamic and Oxygenation Profiles of Remimazolam Combined With Oliceridine Versus Sufentanil in Elderly Patients Undergoing Painless Gastrointestinal Endoscopy: A Randomized, Double-blind, Controlled Trial

Acronym: RMZ-OLI-ENDO

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 16, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.